x+
-cells induced by anti-Le x mAbs and complement when cells were adhered to the endothelium, and the effect of these antibodies on HUVEC. The results indicate that MCF-7 cells can bind to HUVEC, and that MCS-1 but not FC-2.15 mAb inhibit this interaction. Both mAbs can efficiently lyse MCF-7 cells bound to HUVEC in the presence of complement without damaging endothelial cells. We also found a Le x -dependent PMN interaction with HUVEC. Although both anti-Le x mAbs lysed PMN in suspension and adhered to HUVEC, PMN aggregation was only induced by mAb FC-2.15. Blotting studies revealed that the endothelial scavenger receptor C-type lectin (SRCL), which binds Le x -trisaccharide, interacts with specific glycoproteins of M r~2 8 kD and 10 kD from MCF-7 cells. The interaction between Le x+ -cancer cells and vascular endothelium is a potential target for cancer treatment. 
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Introduction
Lewis x (Le x , CD15), also known as SSEA-1 (stage specific antigen-1) is a trisaccharide with the structure Galb(1-4)Fuca(1-3)GlcNAc [1, 2] which is expressed on glycoconjugates in human polymorphonuclear granulocytes (PMN) [3, 4] and in different tumors including breast and colon carcinoma [4, 5] , Hodgkin's lymphoma [6] , and acute promyelocytic leukemia [7] . It has been suggested that Le x is involved in cellular recognition during fertilization, embryogenesis and neural development [8] [9] [10] . The adhesive functions of Le x glycans and Le x -specific C-type lectins have gained recent interest because of the finding that C-type lectin DC-SIGN (dendritic cell-specific ICAM [intercellular adhesion molecule]-3-grabbing nonintegrin) and related lectins specifically bind to Le x glycans on pathogens such as Schistosoma mansoni and Helicobacter pylori, and possibly on cellular targets, allowing them to serve as adhesion molecules [11] . Furthermore, it has been recently proposed that tumor cells can interact with DC-SIGN in dendritic cells through Le x glycans present in tumor Ags, such as CEA, leading to suppression of dendritic cell functions [12] .
Initial adhesion of cancer cells to endothelium can be mediated by the E-selectin-sLe x /sLe a system. SialylLewis x (sLe x ), (NeuNAca2-3Galb1-4(Fuca1-3)GlcNAc) on cancer cells and leukocytes is the major ligand for endothelial E-selectin [13, 14] , along with sLe a , mediating tethering and rolling on activated endothelial cells. To stably adhere to endothelial cells, cancer cells may potentially follow two known routes: an integrin-mediated firm adhesion pathway as shown for melanoma cells [15] , or a non-integrin-mediated pathway based on clustering of endothelial E-selectin or E-selectin ligands, which was proposed for the firm arrest of colon carcinoma cells [16, 17] . For example, Burdick et al. [17] demonstrated that sLe a -negative, sLe x /di-sLe x positive metastatic LS174T colon adenocarcinoma cells adhere to human umbilical vein endothelial cells (HUVEC) through sLe x -glycolipids and sLe
x -glycoproteins that bind to E-selectin. However, numerous rolling cells were still observed after treatment with neuraminidase, suggesting the presence of nonsialylated non-integrin ligands. As it refers to normal PMN, in which sLe x has also been implicated as a counterreceptor for selectins in adhesion to endothelium [14, 18] , glycoproteins containing Le x such as CD11b/CD18 integrin [19] [20] [21] and carcinoembryonic antigen-related cellular adhesion molecule 1 (CEA-CAM1) [22] have also been detected.
Recently, the scavenger receptor C-type lectin (SRCL), another C-type lectin that is highly specific for Le x -trisaccharide was found expressed on endothelial cells [23] . The restricted glycan binding of SRCL and its distribution on vascular endothelial cells suggest that it might have a role in cell adhesion analogous to the leukocyte-endothelial interactions mediated by selectins.
We have previously described the mouse mAb FC-2.15 (IgM/j), which specifically recognizes Le x and induces complement (C¢) mediated lysis of Le x+ -cells, such as the human breast cancer cell line MCF-7 [4, 24, 25] . The mAb FC-2.15 has been assayed in a Phase I clinical trial performed in 11 patients with advanced cancer whose tumors expressed Le x [26] . In this trial, a sustained >50% reduction of breast carcinoma liver metastases was observed. The main toxicity found in 10/11 patients was a profound neutropenia that occurred within 1 h after the start of each mAb infusion and was reversed within 1 h after its discontinuation. FC-2.15 effects on MCF-7 cells and PMN were analyzed both in vitro and in ex vivo circulating blood [27] . FC-2.15 induced in vitro PMN homotypic aggregation and lysis when C¢ was added. However, homotypic aggregation was not common to all Le x+ -cells, since MCF-7 breast cancer cells were lysed in the presence of C¢ but were not aggregated. 
Materials and methods

Antibodies
Anti-Le x mAb FC-2.15 (IgM) was purified as previously described [4] . Anti-Le x mAb MCS-1 (IgG 3 ) was obtained from Cytognos (Salamanca, Spain). Anti-sLe x mAb CSLEX1 (IgM) was obtained from hybridoma HB-8580, American Type Culture Collection (ATCC, Rockville, MD, USA). Anti-CD18-activating mAb KIM185 (IgG 1 ) was provided by Dr. Martyn Robinson (Celltech Therapeutics, Berkshire, UK) [28] ; anti-CD18-blocking mAb TS1/18 [29] was used as mouse ascites and the hybridoma was obtained from ATCC; mAb anti-CD18 MEM-48 (IgG 1 ) [30] and anti-CD11b MEM-170 were kindly provided by Dr.Vá clav Horejsi (Prague, Czech Republic). Other antibodies used were rabbit anti-human von Willebrand factor (DAKO, Glostrup, Denmark), mouse mAbs anti-CD34 (Ig-G 1 )(DAKO), anti-human CD31 (PECAM-1) (IgG 1 ) (Novocastra Lab. Ltd., Newcastle, UK), and anti-human smooth muscle actin (IgG 2a ) (DAKO). In control experiments, normal rabbit serum or different isotypematched control mouse antibodies (Sigma, St. Louis, MI, USA) were used.
Cell cultures
Human umbilical vein endothelial cells (HUVEC) were isolated from cord segments from normal women with negative serology for Hepatitis B and C, HIV and CMV, and submitted to cesarean for medical reasons. The umbilical cords use for this research was authorized by the Institutional Review Boards of the Hospital Naval Pedro Mallo and the Hospital Rivadavia, Buenos Aires, Argentina, and the patients gave informed consent. Umbilical cords were treated with 0.5 mg/ml collagenase according to Jaffé et al. [31] . Primary cultures were grown in RPMI-1640 medium supplemented with 20% heat-inactivated AB human serum, 100 U/ml penicillin, 100 lg/ml streptomycin, 2 mM L-glutamine, 100 U/ml heparin, and 150 lg/ml endothelial cell growth supplement (Sigma) in tissue culture flasks (25 cm 2 ). HUVEC were typically selected for experimental use at passages 2-4. In most experiments, monolayers were pretreated with different concentrations (1-10 lg/ml) of bacterial lipopolysaccharide (LPS, Sigma,) for 4 h at 37°C, to induce expression of adhesion molecules.
The human breast cancer cell line MCF-7 [32] was grown in Dulbecco's modified-Eagle's medium (DMEM)/Ham's nutrient mixture F-12 (1:1) supplemented with 10% fetal bovine serum, 2 mM glutamine, 10 lg/ml insulin, 100 U/ml penicillin, and 100 lg/ml streptomycin. Exponentially growing cells were harvested by treatment with 0.25% trypsin-0.038% EDTA.
Isolation of PMN PMN were obtained from fresh human blood of normal volunteers, who gave informed consent. Briefly, heparinized whole blood was fractionated by dextran sedimentation, and the upper fraction was submitted to Ficoll-Hypaque gradient centrifugation. PMN were recovered from the pellet, and the remaining erythrocytes were lysed in 0.1 mM EDTA, 10 mM KCO 3 H, 155 mM NH 4 Cl during 10 min. After washing in PBS, PMN (purity: 93%) were resuspended in Hanks' balanced salt solution and kept on ice until used.
Immunofluorescence HUVEC were grown on untreated cover slides (diameter: 12 mm) placed in 24-well microplates. In some experiments, PMN or MCF-7 were adhered to HUVEC and immunostaining was performed after fixation in 3% paraformaldehyde. When necessary, permeabilization was carried out with 0.05% saponin in PBS. HUVEC characterization was performed using the following primary antibodies: polyclonal antibody anti-von Willebrand factor, anti-CD34, and anti-muscle a-actin. Normal rabbit serum or different isotype-matched mouse immunoglobulins were used as controls. Secondary antibodies were Cy2-conjugated goat anti-rabbit IgG (DAKO), R-phycoerythrin-conjugated F(ab¢) 2 4 cells/well) were added to each well, and incubated at 37°C for 30 min in a CO 2 incubator. Unbound cells were washed twice with PBS (200 ll/well). Bound cells were lysed with 0.2 N NaOH (200 ll/well); the medium from each well was collected and filtered through GFA papers (Whatman, Middlesex, UK), and the radioactivity was counted in a beta counter (Wallac, Pharmacia). MCF-7 cells were digested with neuraminidase from Clostridium perfringens (5 U/ml) in 50 mM sodium citrate, pH 4.5 for 1 h at 37°C.
Adhesion of PMN to HUVEC
Assays were measured by the myeloperoxidase method [33] . Exponentially growing HUVEC (10 4 /well) were cultured to confluence on 96-well microplates precoated with 1% gelatin (Sigma) and incubated for 2 days. After removing growth medium, fresh medium (100 ll/well) containing various concentrations of LPS (1-10 lg/ml) were added and incubated at 37°C for 4 h in a CO 2 incubator. PMN (25 ll/well) were added to the wells and the plate was incubated for 5 min at 37°C in a CO 2 incubator. Unbound cells were removed by washing three times in PBS containing 2% fetal bovine serum (200 ll/well). Citrate buffer (0.1 M, pH 4.5) containing 0.1% Nonidet P-40 (100 ll/well) was added to each well. After 10 min, a 2-fold o-phenylenediamine (OPDA, Sigma) solution (8 mg OPDA, 8 ll of H 2 O 2 in 8 ml citrate buffer) (100 ll/well) was added to each well. After incubation at room temperature for 30 min, 4 N H 2 SO 4 (100 ll/well) was added to stop the reaction, and OD 450 nm was measured. For blocking experiments, LPS-treated HUVEC were incubated with different concentrations of mAbs (100 ll/well) for 1 h at 37°C in a CO 2 incubator; then, PMN resuspended in each mAb were added to the corresponding well. Isotype-matched irrelevant antibodies or PBS were used as controls. PMN were digested with neuraminidase from Clostridium perfringens (5 U/ml) in 50 mM sodium citrate, pH 4.5 for 1 h at 37°C.
Complement-dependent cytotoxicity (CDC)
A 51 Cr-release assay was used to test the ability of FC-2.15 to mediate complement-dependent cytotoxicity. Experiments were performed on isolated target cells (PMN or MCF-7) or on target cells adhered to monolayers of HUVEC. For experiments with isolated target cells, PMN or MCF-7 cells (2.5 · 10 6 /ml) were labeled with 51 Cr (Na 2 51 CrO 4 , sp. act.: 445.75 mCi/mg; 150 lCi/ ml; Perkin Elmer, Boston, MA, USA) for 2 h at 37°C, and washed three times with PBS. 51 Cr-labeled cells (10 5 ) in 100 ll culture medium plus 100 ll human serum as the source of complement were incubated with mAb FC-2.15 (0, 2.5, 10, 20 lg/ml) for different times at 37°C [27] . Parallel incubations containing target cells resuspended in 200 ll medium alone or in 200 ll 0.1 M HCl were performed to determine spontaneous and total 51 Cr release, respectively. At the end of the incubation period, the cells were centrifuged, and the supernatant radioactivity was determined in a gamma counter. Negative control experiments were performed with mouse IgM (20 lg/ml, DAKO) instead of FC-2.15. Each point was assayed in triplicate and the percentage of specific cytolysis was calculated with the formula:
Specific lysisð%Þ ¼ experimental releaseðcpmÞ À spontaneous releaseðcpmÞ maximal releaseðcpmÞ À spontaneous releaseðcpmÞ 4 /well) were loaded on unlabeled HUVEC monolayers, and adhesion was conducted for 30 min at 37°C. After adhesion, the wells were washed twice to eliminate unbound cells, and 100 ll of FC-2.15 (0-20 lg/ ml) plus 100 ll of human serum as C¢ source were added. Incubations were performed for 90 min at 37°C and the percentage of specific cytolysis was determined as described above.
To assess the lytic effect of bound cells undergoing FC-2.15-dependent CDC on HUVEC monolayers, HUVEC (10 4 /well) were cultured in 96-well microplates to confluence, and then stimulated with LPS (1 lg/ml) for 4 h at 37°C. Each HUVEC monolayer was labeled with 51 Cr (5 ll/well) for 2 h at 37°C, and washed three times with PBS.
51 Cr-labeled HUVEC were incubated with unlabeled PMN or unlabeled MCF-7 cells for 30 min at 37°C. After adhesion, unbound cells were washed twice with PBS, and 100 ll of FC-2.15 (20 lg/ml) plus 100 ll of human serum were added. Incubations were performed for 90 min at 37°C. Parallel incubations in medium alone or in 0.1 M HCl were performed to determine spontaneous and total 51 Cr release, respectively. Negative control experiments were performed with mouse IgM (20 lg/ml, DAKO) instead of FC-2.15. Each point was assayed in triplicate, and the specific cytolysis percentage was calculated as described above. When indicated, untreated PMN or fMLP-activated PMN (10 -7 M fMLP) were tested for FC-2.15-dependent CDC on HUVEC monolayers. Cytotoxicity on MCF-7 and PMN in suspension mediated by anti-Le x mAbs (FC-2.15 or MCS-1) plus C¢ was evaluated by the MTT assay. This method is based on the reduction of the tetrazolium salt MTT into a dark blue formazan crystal which production is proportional to the number of viable cells. Control cells were treated with human serum as a source of C¢ in the absence of anti-Le x mAbs. Treated cells were incubated in the presence of anti-Le x mAbs plus C¢. Briefly, MTT (2.5 mg/ml) was added to the cells and incubated 4 h at 37°C. Cells were centrifuged, supernatants were discarded, and the colored formazan crystals were dissolved in 0.01 N H 2 SO 4 . Absorbance (A) was read in a microplate reader at 540 nm using absorbance at 630 nm as a reference. Data expressed as lysis percentages were calculated with the formula: %Lysis = 100% -[A value of sample/A value of control] · 100 [34] .
In vitro aggregation assay Suspensions of PMN (1.5 · 10 6 cells/ml) were incubated for 1 h at 37°C with gentle agitation in the presence of different concentrations of FC-2.15. Samples were observed under a phase contrast microscope (Axioplan, Carl Zeiss, Gö ttingen, Germany). The percentage of aggregated PMN was determined as: (aggregated/non-aggregated · 100). To analyze the kinetics of FC-2.15 induced PMN aggregation, samples were taken at different times, fixed with 4% formaldehyde, and the percentage of aggregated PMN was determined as above.
In other experiments, aggregation assays were performed by incubating PMN under different conditions such as 4°C, 0.04% sodium azide, 25 mM 2-deoxy-D-glucose (2dGlc) (4 min, at 37°C), 1 mM iodoacetic acid (IAA), or fixation in 4% formaldehyde (10 min). PMN aggregation induced by fMLP (4 · 10 -7 M, Sigma) or by the activating mAb against human b 2 integrin KIM185 (20 lg/ml) were also determined. When indicated, a preincubation of PMN with the blocking mAb against human b 2 integrin TS1/18 (ascites, 1/75) during 1 h at 37°C was performed, and this mAb was maintained during the aggregation assay in the presence of FC-2.15 or KIM185 (both at 20 lg/ml).
Western blots
Membrane extracts were prepared as follows. The cells were homogenized in 10 mM Tris-HCl, 1.5 mM EDTA, 1 mM PMSF, pH 7.4 with a polytron (IKA Werk, Germany). After ultracentrifugation (100,000 · g, 1 h) of crude extracts, membrane pellets were solubilized in NP-40 buffer (1% NP-40, 0.1 M Tris-HCl pH 8.2, 0.15 M NaCl, 5 lg/ml pepstatin A, 10 lg/ml aprotinin, 5 lg/ml leupeptin, 1 mM PMSF) for 30 min on ice. Insoluble material was removed by centrifugation, and the supernatant was used for further work. Protein samples were run in SDS-PAGE and transferred to nitrocellulose membrane (Sigma, 0.45 lm). After blocking with 3% dried skim milk in PBS for 1 h, blots were incubated with primary antibodies (overnight at 4°C), washed in 0.05% Tween 20-PBS, and developed using alkaline phosphatase-conjugated goat anti-mouse antibodies (Jackson Immuno Research, West Grove, PA, USA). Finally, blots were visualized using nitroblue tetrazolium/5-Bromo-4-chloro-3-indolylphosphate (Promega, Madison, WI, USA).
Immunoprecipitation
About 800 lg of 1% NP-40 membrane fraction preparation were used for each immunoprecipitation and incubated with 6 lg of mAb MEM-48, MEM-170, or isotype-matched mouse immunoglobulins overnight at 4°C. Complexes were bound to Protein G-Sepharose (Amersham Pharmacia Biotech AB, Uppsala, Sweeden) for 2 h at 4°C. After washing with NP-40 buffer, immunoprecipitates were eluted under non-reducing conditions with SDS-PAGE sample buffer, run in 7.5% SDS-PAGE and blotted onto nitrocelullose. Western blots were developed with MEM-48, MEM-170, FC-2.15 mAbs or with isotype-matched mouse immunoglobulins (20 lg/ml).
Blotting with the scavenger receptor C-type lectin (SRCL)
The trimeric extracellular domain of human SRCL was prepared and labeled as previously described [23] . Membrane extracts from MCF-7 cells were prepared as described before, separated on 17.5% gels which were transferred to nitrocellulose and probed with the labeled receptor following the procedure previously used to study purified glycoproteins [23] .
Results
Comparative expression of Le x in MCF-7, PMN, and HUVEC To characterize our experimental model, we first investigated by immunofluorescence if Le x was expressed in HUVEC. Primary cultures of HUVEC grew as monolayers with a cobblestone-like morphology, high levels of von Willebrand factor (vWF) and lack of Le x epitope expression (Fig. 1a) ; PMN were added to HUVEC to serve as positive controls of FC-2.15 reactivity (Fig. 1b) , as previously demonstrated [27] . Flow cytometry studies with mAbs FC-2.15 and MCS-1, or CSLEX1, respectively, confirmed the lack of Le x and sLe x expression in HUVEC (Fig. 2) [35] . On the contrary, MCF-7 and PMN showed high levels of Le x and sLe x surface expression (Fig. 2) .
Adhesion of MCF-7 cells and PMN to HUVEC. Comparative effects of antibodies anti-Le x
Since the mechanism of PMN adhesion to human endothelia involves both sugar-ligand interaction (selectin-mediated rolling) and integrin activation (strong adhesion), we tested if Le x plays a role in the adhesion of both MCF-7 tumor cells and PMN to LPSactivated or non-activated HUVEC. To establish the optimal experimental setting, the effect of HUVEC activation on PMN adhesion was first measured. The adhesion of PMN to HUVEC augmented after LPS activation, attaining a maximum increase of three-fold at 1 lg/ml LPS (Fig. 3b) . Similarly, MCF-7 cells binding to non-activated and LPS-activated HUVEC was measured, and as shown in Fig. 3a the percentages of cell binding were 60% and 80%, respectively (Fig. 3a) . LPS did not increase binding of MCF-7 cells to endothelial cells to an appreciable extent (Fig. 3a, lower  panel) when compared to PMN binding to LPS-activated HUVEC (Fig. 3b) . However, since PMN binding was increased after LPS-treatment, it seemed reasonable to maintain LPS activation in all experiments performed thereafter. To investigate the role of Le x epitopes on this adhesion, we incubated MCF-7 cells (5 · 10 4 cells/well) in the presence of two different anti-Le x mAbs, FC-2.15 (IgM) and MCS-1 (IgG 3 ). Adhesion was blocked by approximately~57% (remaining adhesion: 43 ± 8.5%) in the presence of 50 lg/ml anti-Le x MCS-1, whereas no inhibition was observed with FC-2.15, again at 50 lg/ml (Fig. 3c) . When the effects of anti-Le x mAbs on PMN adhesion to HUVEC were measured, it was also found that only MCS-1 significantly reduced (~63-95%) the level of PMN adhesion, whereas no inhibition was observed with FC-2.15 (Fig. 3d) . The anti-sLe
x mAb CSLEX1 was also tested, and an inhibition of~57% was found at 50 lg/ml (remaining adhesion: 43 ± 9.8%).
To confirm the role of sialic acid residues on PMN adhesion to HUVEC, assays were performed after PMN treatment with neuraminidase. In Fig. 3e , it may be observed that neuraminidase treatment inhibited PMN adhesion. For instance, when 2 · 10 5 PMN/well were loaded, adhesion was inhibited by approximatelỹ 45% in neuraminidase-treated as compared to control PMN (Fig. 3e) . Therefore, in spite of the removal of sialic acid by neuraminidase treatment,~55% of PMN adhesion to HUVEC is still retained. This residual adhesion might be due to integrin-dependent mechanisms and/or to the existence of other interactions such as those mediated by Le x determinants, since low affinity binding of Le x -residues to E-selectin has been previously demonstrated [36] . Regarding sLe x mediated-MCF-7 binding to HUVEC, although mAb CSLEX1 did not block adhesion (data not shown), neuraminidase treatment of MCF-7 cells partially diminished this binding (42 ± 10%) (Fig. 3c , right panel), which might indicate that the selectin pathway could also participate in this adhesion.
FC-2.15 antibody mediates complement-dependent cytotoxicity (CDC) on MCF-7-cells and PMN. Comparative effects on adhered and isolated cells
To test the ability of FC-2.15 to mediate CDC on MCF-7, PMN and HUVEC, 51 Cr-release assays were performed at different FC-2.15 concentrations and incubation times (30, 60 , and 90 min). Incubations of 90 min gave the highest cytolysis percentages (data not shown), so all the following experiments were performed at this incubation time. For MCF-7 cells in suspension, the lysis percentages obtained were 84.5 ± 3.8%, 64.0 ± 16.4%, 29.75 ± 0.1% for FC-2.15 concentrations of 20, 10, and 2.5 lg/ml, respectively (Fig. 4a) . The lysis of control IgM-treated (20 lg/ml) MCF-7 cells in suspension was 3.6 ± 1.9% (data not shown). For FC-2.15 concentrations of 20, 10, and 2.5 lg/ml, the lysis of PMN in suspension were 97 ± 4.2%, 89.5 ± 14.6%, and 59.8 ± 11.7 %, respectively (Fig. 4a) . The lysis of control IgM-treated (20 lg/ml) PMN was 8.9 ± 0.3% (data not shown). Therefore, low concentrations of FC-2.15 (2.5 lg/ml) produced higher levels of cytolysis on PMN than MCF-7 cells when both were in suspension.
Afterwards, we studied FC-2.15-mediated CDC of MCF-7 or PMN once adhered to HUVEC monolayers, for which unlabeled HUVEC were incubated with 51 Cr-labeled MCF-7 cells or PMN. The opposite situation to that observed with suspended cells was found, since FC-2.15 produced a marked cytolysis (~50%) of adherent MCF-7 starting at 2.5 lg/ml and attaining~90-100% lysis at 10-20 lg/ml (Fig. 4b) . Lysis of adherent PMN was only observed at 10 and 20 lg/ml (~60% and~90%, respectively). To summarize, when suspended cells were analyzed, PMN were more sensitive than MCF-7 cells to CDC mediated by low concentrations (2.5 lg/ml) of FC-2.15 while the opposite was observed for adherent cells.
Whether the CDC lysis of adhered cells had any deleterious effect on underlying HUVEC was also evaluated by labeling HUVEC monolayers grown in 96-well microplates with 51 Cr, before the addition of unlabeled target cells. When 51 Cr-labeled HUVEC were incubated with FC-2.15 (20 lg/ml) and C¢ in the absence of PMN or MCF-7, insignificant levels of HUVEC cytolysis were observed (data not shown). In the presence of unlabeled MCF-7 adhering to 51 Crlabeled HUVEC, no lytic effects on HUVEC were observed (Fig. 4c) in spite of the fact that adherent cells were undergoing FC-2.15-dependent CDC (Fig. 4b) . On the contrary, when PMN adhered to 51 Cr-labeled HUVEC underwent CDC,~20%
51 Crrelease from HUVEC was observed, which was statistically significant (P < 0.05, Fig. 4c) .
Surprisingly, fMLP-activated adherent PMN showed no lytic effects on 51 Cr-labeled HUVEC as compared to adherent non-activated PMN, both undergoing FC-2.15-dependent CDC. In summary, there was no damage to HUVEC in the presence of adherent MCF-7 undergoing CDC and the injury resulted to be not severe in the presence of PMN undergoing CDC. (Fig. 4d) , although the lytic effect on PMN was similar (Fig. 4e) .
FC-2.15 antibody aggregates PMN but MCS-1 antibody does not
We have previously reported that FC-2.15 induces PMN homotypic aggregation, which could be a cause of the neutropenia observed in clinical trials [26] . In order to disclose if PMN aggregation only required recognition of Le x epitopes or if other factors such as multivalency of IgM or integrins activation were also involved, we performed further experiments. First, different FC-2.15 concentrations (0-20 lg/ml) and incubation periods were tested. FC-2.15 (20 lg/ml) induced a strong and rapid PMN aggregation, with only 25% PMN remaining isolated (Fig. 5a ). Time-course experiments performed at a saturating concentration of FC-2.15 (20 lg/ml) demonstrated that aggregation was already detected after 30 s, and maximal effects were obtained after 15 min (Fig. 5b) . When we tested whether aggregation only depends on Le x -specificity, we found that was not the case since aggregation was not induced by another anti-Le x mAb MCS-1 (IgG 3 ) (Fig. 5c) . Therefore, additional factors to Le x specificity were necessary. Other experiments performed demonstrated that this aggregation did not require energy, since it was not modified by incubation at 4°C, or with 0.04% sodium azide, 1 mM iodoacetic acid and 25 mM 2-deoxy-D-glucose (data not shown). However, fixation in formaldehyde inhibited aggregation (data not shown). Taken together, these findings suggest that aggregation requires a conformational flexibility of the cell membrane but does not require energy. Since b 2 integrin (CD11b/CD18) has been shown to be involved in PMN homotypic aggregation [37] and to contain Le x epitopes, the possibility was explored that FC-2.15 could bind to these Le x epitopes and induce the aggregation process due to its multivalency (absent in MCS-1). To explore this possibility, we compared FC-2.15-induced PMN aggregation to that induced by Fig. 6a) . Therefore, b 2 integrin activation pathway might be partially involved in FC-2.15-mediated PMN aggregation. Afterwards, we explored if both CD11b and CD18 integrins contained Le x oligosaccharides recognized by Le x mAbs as described [19] [20] [21] . For this purpose, immunoprecipitation of PMN membrane extracts with anti-CD11b MEM-170 and anti-CD18 MEM-48 followed by Western blots developed with FC-2.15, MEM-170, and MEM-48 were performed and confirmed the presence of Le x in both subunits of this integrin (Fig. 6b) . The band of 180 kD is CD11b and the one of 95 kD is CD18. During immunoprecipitation with each anti-integrin subunit mAb, there was co-precipitation of the other integrin subunit. The CD11b band was more readly detected with mAb MEM-170 although a slight cross-reaction, presumably with CD18, was observed. mAb FC-2.15 recognizes both chains of the integrin, since they both carry Le x epitopes.
The scavenger receptor C-type lectin may provide a mechanism for MCF-7 cell binding to HUVEC
The ability of MCS-1 mAb to inhibit MCF-7 binding to HUVEC confirmed the importance of the Le x epitope in this interaction. Since the scavenger receptor C-type lectin (SRCL) is found on endothelial cells and binds Le x with high selectivity, it is a strong candidate for mediating this tumor cell-endothelium interaction. In order to confirm the ability of SRCL to bind Le x on MCF-7 cells, 125 I-labeled extracellular domain of the receptor was used to probe membrane proteins from MCF-7 cells. The results showed that the receptor bound efficiently two main glycoproteins, M r~2 8 kD and 10 kD, in the cell membranes (Fig. 7b) . Thus, MCF-7 cells express Le x on specific surface glycoproteins. These low M r glycoproteins that bind to the SRCL receptor were not detected by anti-Le x mAbs by immunoblotting (Fig. 7a) , probably reflecting differences in the preferred spacing and presentation of sugar epitopes for the antibodies and SRCL.
Discussion
In this work, we have confirmed that MCF-7 cancer cells and PMN bind to HUVEC, as previously shown [33, 38] . Subsequently, we have demonstrated that the adhesion of both cell types to LPS-activated HUVEC was partially dependent on Le x epitopes. This conclusion was based on the fact that adhesion could be blocked by the anti-Le x mAb MCS-1, but not by FC-2.15, suggesting different specificities. Since both mAbs react with different glycoprotein species (Fig. 7a) , we suggest that MCS-1 recognizes molecules essential for adhesion, whereas FC-2.15 does not. Other authors also showed differential binding of anti-Le x mAbs [22, 39] . For instance, three anti-Le x mAbs which bind to granulocyte glycolipids have been studied, and their binding revealed differential reactivity [40] . Comparison of fine specificities between MCS-1 and FC-2.15 will require further studies, such as crystallographic analysis of each antibody in complex with its Le x antigen as reported by van Roon et al. [41] . The adhesive function of Le x , partially related to P-selectin binding [6] , has also been demonstrated in Hodgkin's lymphoma-derived L428 cells.
In this paper, we also described that MCF-7 cells possess, among other glycoproteins, ligands for the endothelial scavenger receptor C-type lectin (SRCL) [23] , which could mediate adhesion of cancer cells to vascular endothelium in a manner analogous to the leukocyte-endothelial interactions mediated by selectins. Further characterization of the specific ligands present in breast cancer MCF-7 cells remains to be performed.
We then examined the effect of anti-Le x mAbs on lysis of tumor or normal cells. HUVEC did not suffer CDC in the presence of anti-Le x mAbs, as expected due to their undetectable Le x surface expression [35] . In this paper, we demonstrated that both anti-Le x mAbs efficiently lysed Le x+ -MCF-7 cells in the presence of C¢, both in suspension and adhered to HU-VEC. Moreover, we have shown that the lysis of adherent MCF-7 did not damage endothelial cells. As it regards to PMN lysis, it was achieved by FC-2.15 and MCS-1, either in suspension as already described for FC-2.15 [27] or adhered to HUVEC. However, in the latter case, lysis of PMN by anti-Le x mAb induced a certain degree of HUVEC lysis, which might be due to the discharge of different enzymes present in PMN granules, whose potential clinical significance is unknown. Different anti-Le x antibodies have been used in the immunotherapy of hematological malignancies [42] and solid tumors [26] . When assayed in a Phase I clinical trial, FC-2.15 induced the remission of liver metastases in a breast cancer patient, albeit at the expense of a neutropenia which was rapidly reversible after the end of the infusion. We do not know if the observed neutropenia was due to PMN lysis, PMN aggregation or a combination of both mechanisms. Homotypic neutrophil aggregation mediated by antiLe x mAb has already been observed by us [27] and other authors [43] . In this paper, we have demonstrated that it is induced by FC-2.15 (IgM) but not by MCS-1 (IgG 3 ), which suggests that FC-2.15-mediated aggregation would depend on the combined effects of Le xspecificity and multivalency. A compounding factor could be that the PMN integrins CD18 and CD11b carry Le x epitopes, and anti-Le x mAbs binding could induce integrin activation and PMN aggregation. This assumption is supported by the fact that FC-2.15-mediated PMN aggregation was partially blocked by the b 2 integrin inhibitor mAb TS1/18. If PMN aggregation contributes significantly to neutropenia, MCS-1, which does not induce it, could hold more therapeutic promise than FC-2.15.
The interaction between tumor cells and endothelium through Le x epitopes could provide a target for inhibition by mAbs such as those investigated in this study, and it could therefore have implications in the prevention of tumor cell metastasis. Although the release of cancer cells during surgery has not been extensively studied, due in great part to technical difficulties in identifying circulating tumor cells, in a few cases it has been documented. For instance, Wong et al. [44] have demonstrated that, after hepatocellular carcinoma surgery, tumor cells are detached and may spread hematogeneously. Similarly, in laparoscopic lobectomy, Yamashita et al. [45] have demonstrated that cancer cells were released into circulation. Based on these results, one could speculate that peri-surgical infusion of anti-Le x mAbs in patients submitted to surgery of Le x -expressing tumors, such as breast and colorectal carcinoma, could be useful to prevent tumor metastases, either by lysing tumor cells in circulation detached from large tumors, or by preventing their attachment to endothelia. In summary, MCS-1 would appear to be a better candidate for therapeutic purposes than FC-2.15, since it efficiently mediates Le x+ -tumor cell CDC, it blocks binding of Le x+ -cells to vascular endothelia and it does not induce PMN aggregation.
